Editas Medicine, Inc. (EDIT)
3.075
0.00 (0.00%)
USD |
NASDAQ |
Sep 02, 16:00
3.06
-0.02
(-0.49%)
After-Hours: 20:00
Editas Medicine Cash and Short Term Investments (Quarterly) : 211.64M for June 30, 2026
Cash and Short Term Investments (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash and Short Term Investments (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 211.64M |
| March 31, 2026 | 123.65M |
| December 31, 2025 | 146.64M |
| September 30, 2025 | 165.65M |
| June 30, 2025 | 178.50M |
| March 31, 2025 | 220.96M |
| December 31, 2024 | 269.91M |
| September 30, 2024 | 265.09M |
| June 30, 2024 | 279.11M |
| March 31, 2024 | 296.17M |
| December 31, 2023 | 323.11M |
| September 30, 2023 | 349.62M |
| June 30, 2023 | 431.97M |
| March 31, 2023 | 318.44M |
| December 31, 2022 | 344.27M |
| September 30, 2022 | 419.62M |
| June 30, 2022 | 452.56M |
| March 31, 2022 | 488.36M |
| December 31, 2021 | 499.84M |
| September 30, 2021 | 557.84M |
| June 30, 2021 | 610.55M |
| March 31, 2021 | 625.33M |
| Date | Value |
|---|---|
| December 31, 2020 | 402.11M |
| September 30, 2020 | 495.30M |
| June 30, 2020 | 598.72M |
| March 31, 2020 | 414.99M |
| December 31, 2019 | 457.14M |
| September 30, 2019 | 332.62M |
| June 30, 2019 | 317.93M |
| March 31, 2019 | 342.06M |
| December 31, 2018 | 368.96M |
| September 30, 2018 | 337.49M |
| June 30, 2018 | 344.08M |
| March 31, 2018 | 358.82M |
| December 31, 2017 | 329.14M |
| September 30, 2017 | 295.69M |
| June 30, 2017 | 324.80M |
| March 31, 2017 | 351.55M |
| December 31, 2016 | 185.32M |
| September 30, 2016 | 200.19M |
| June 30, 2016 | 217.97M |
| March 31, 2016 | 229.52M |
| December 31, 2015 | 143.50M |
Cash and Short Term Investments Definition
Represents the sum of cash and short term investments.
Cash and Short Term Investments (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash and Short Term Investments (Quarterly) Benchmarks
| Recursion Pharmaceuticals, Inc. | 551.07M |
| Geron Corp. | 302.74M |
| Halozyme Therapeutics, Inc. | 231.00M |
| Novavax, Inc. | 719.34M |
| AVITA Medical, Inc. | 11.14M |